<DOC>
	<DOC>NCT01556451</DOC>
	<brief_summary>This study will evaluate the safety, tolerability, and immunogenicity of ZOSTAVAX™ in Korean adults. Approximately 180 herpes zoster history negative subjects ≥ 50 years of age will be enrolled in the study. Each subject will receive a single dose of ZOSTAVAX™. No statistical hypothesis testing will be conducted in the study.</brief_summary>
	<brief_title>ZOSTAVAX™ Safety and Immunogenicity in Korean Adults (V211-034)</brief_title>
	<detailed_description />
	<mesh_term>Herpes Zoster</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>No fever on day of vaccination Females have a negative pregnancy test and use an acceptable method of birth control, or are postmenopausal Underlying chronic illness must be stable History of hypersensitivity reaction to any vaccine component Prior history of herpes zoster Prior receipt of varicella or zoster vaccine Pregnant or breastfeeding Have recently received immunoglobulins or blood products other than autologous blood transfusion Received any inactivated other live virus vaccine within 4 weeks prior to vaccination, or is expected to received any other live virus vaccine during the duration of the study Received any inactivated vaccine within 7 days prior to vaccination, or is expected to receive any inactivated vaccine during the duration of the study Use of immunosuppressive therapy Known or suspected immune dysfunction Use of nontopical antiviral therapy with activity against herpes virus Known or suspected active untreated tuberculosis</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>